CRDF vs. XFOR, VCXB, VXRT, CLLS, CRDL, CGEN, VIGL, GNFT, ADVM, and SCLX
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include X4 Pharmaceuticals (XFOR), 10X Capital Venture Acquisition Corp. III (VCXB), Vaxart (VXRT), Cellectis (CLLS), Cardiol Therapeutics (CRDL), Compugen (CGEN), Vigil Neuroscience (VIGL), Genfit (GNFT), Adverum Biotechnologies (ADVM), and Scilex (SCLX). These companies are all part of the "biological products, except diagnostic" industry.
X4 Pharmaceuticals (NASDAQ:XFOR) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, community ranking, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.
X4 Pharmaceuticals presently has a consensus price target of $3.00, indicating a potential upside of 223.14%. Cardiff Oncology has a consensus price target of $10.50, indicating a potential upside of 189.26%. Given Cardiff Oncology's higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than Cardiff Oncology.
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 1.1% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 6.3% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, X4 Pharmaceuticals had 8 more articles in the media than Cardiff Oncology. MarketBeat recorded 10 mentions for X4 Pharmaceuticals and 2 mentions for Cardiff Oncology. X4 Pharmaceuticals' average media sentiment score of 0.65 beat Cardiff Oncology's score of 0.10 indicating that Cardiff Oncology is being referred to more favorably in the news media.
X4 Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.
Cardiff Oncology has higher revenue and earnings than X4 Pharmaceuticals. Cardiff Oncology is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals received 33 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 65.74% of users gave X4 Pharmaceuticals an outperform vote while only 62.30% of users gave Cardiff Oncology an outperform vote.
X4 Pharmaceuticals has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -6,594.92%. X4 Pharmaceuticals' return on equity of -54.54% beat Cardiff Oncology's return on equity.
Summary
Cardiff Oncology beats X4 Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRDF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
